Take­da con­tin­ues glob­al R&D re­boot with a new joint ven­ture with PRA

Christophe We­ber, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Take­da Phar­ma­ceu­ti­cal Co., speaks dur­ing the 18th Nikkei Glob­al Man­age­ment Fo­rum in Tokyo, Japan  (CRED­IT: To­mo­hi­ro Ohsu­mi/Bloomberg via Get­ty Im­ages)

Christophe We­ber has un­leashed some tidal forces in re­struc­tur­ing Take­da’s 236-year-old busi­ness. And they’re tak­ing an­oth­er big step in the process by set­ting up an R&D joint ven­ture with the big CRO PRA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER